{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T18:04:51Z","timestamp":1777658691052,"version":"3.51.4"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2019,1,11]],"date-time":"2019-01-11T00:00:00Z","timestamp":1547164800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2019,1,11]],"date-time":"2019-01-11T00:00:00Z","timestamp":1547164800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS J"],"DOI":"10.1208\/s12248-018-0289-3","type":"journal-article","created":{"date-parts":[[2019,1,11]],"date-time":"2019-01-11T16:33:17Z","timestamp":1547224397000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Tumor-Targeted Chemoimmunotherapy with Immune-Checkpoint Blockade for Enhanced Anti-Melanoma Efficacy"],"prefix":"10.1208","volume":"21","author":[{"given":"Man","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuting","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chaoqun","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiaojie","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yingke","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xingli","family":"Cun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qianwen","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xian","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheng","family":"Yin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhirong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qin","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,1,11]]},"reference":[{"key":"289_CR1","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/nrc3958","volume":"15","author":"HE Barker","year":"2015","unstructured":"Barker HE, Paget JTE, Khan AA, Harrington KJ. The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence. Nat Rev Cancer. 2015;15:409\u201325.","journal-title":"Nat Rev Cancer"},{"key":"289_CR2","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.coi.2015.12.003","volume":"39","author":"AM Cook","year":"2016","unstructured":"Cook AM, Lesterhuis WJ, Nowak AK, Lake RA. Chemotherapy and immunotherapy: mapping the road ahead. Curr Opin Immunol. 2016;39:23\u20139.","journal-title":"Curr Opin Immunol"},{"issue":"9","key":"289_CR3","doi-asserted-by":"crossref","first-page":"e955691","DOI":"10.4161\/21624011.2014.955691","volume":"3","author":"O Kepp","year":"2014","unstructured":"Kepp O, Senovilla L, Vitale I, Vacchelli E, Adjemian S, Agostinis P, et al. Consensus guidelines for the detection of immunogenic cell death. OncoImmunology. 2014;3(9):e955691.","journal-title":"OncoImmunology"},{"issue":"17","key":"289_CR4","doi-asserted-by":"crossref","first-page":"3341","DOI":"10.1016\/j.vaccine.2010.08.002","volume":"29","author":"F Steinhagen","year":"2011","unstructured":"Steinhagen F, Kinjo T, Bode C, Klinman DM. TLR-based immune adjuvants. Vaccine. 2011;29(17):3341\u201355.","journal-title":"Vaccine"},{"issue":"2","key":"289_CR5","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1093\/annonc\/mdl158","volume":"18","author":"G Parmiani","year":"2007","unstructured":"Parmiani G, Castelli C, Pilla L, Santinami M, Colombo MP, Rivoltini L. Opposite immune functions of GM-CSF administered as vaccine adjuvant in cancer patients. Ann Oncol. 2007;18(2):226\u201332.","journal-title":"Ann Oncol"},{"issue":"12","key":"289_CR6","doi-asserted-by":"crossref","first-page":"5451","DOI":"10.4049\/jimmunol.1490019","volume":"192","author":"SA Rosenberg","year":"2014","unstructured":"Rosenberg SA. IL-2: the first effective immunotherapy for human cancer. J Immunol. 2014;192(12):5451\u20138.","journal-title":"J Immunol"},{"key":"289_CR7","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jconrel.2016.02.043","volume":"228","author":"M Li","year":"2016","unstructured":"Li M, Zhao M, Fu Y, Li Y, Gong T, Zhang Z, et al. Enhanced intranasal delivery of mRNA vaccine by overcoming the nasal epithelial barrier via intra- and paracellular pathways. J Control Release. 2016;228:9\u201319.","journal-title":"J Control Release"},{"key":"289_CR8","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.actbio.2017.10.019","volume":"64","author":"M Li","year":"2017","unstructured":"Li M, Li Y, Peng K, Wang Y, Gong T, Zhang Z, et al. Engineering intranasal mRNA vaccines to enhance lymph node trafficking and immune responses. Acta Biomater. 2017;64:237\u201348.","journal-title":"Acta Biomater"},{"issue":"5","key":"289_CR9","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1007\/s11515-012-1194-2","volume":"7","author":"PB Subrahmanyam","year":"2012","unstructured":"Subrahmanyam PB, Webb TJ. Boosting the immune response: the use of iNKT cell ligands as vaccine adjuvants. Front Biol. 2012;7(5):436\u201344.","journal-title":"Front Biol"},{"key":"289_CR10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jconrel.2016.05.050","volume":"235","author":"S Shi","year":"2016","unstructured":"Shi S, Zhou M, Li X, Hu M, Li C, Li M, et al. Synergistic active targeting of dually integrin \u03b1v\u03b23\/CD44-targeted nanoparticles to B16F10 tumors located at different sites of mouse bodies. J Control Release. 2016;235:1\u201313.","journal-title":"J Control Release"},{"issue":"12","key":"289_CR11","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.7150\/thno.16184","volume":"6","author":"Y Yang","year":"2016","unstructured":"Yang Y, Tai X, Shi K, Shaobo R, Qiu Y, Zhang Z, et al. A new concept of enhancing immuno-chemotherapeutic effects against B16F10 tumor via systemic administration by taking advantages of the limitation of EPR effect. Theranostics. 2016;6(12):2141\u201360.","journal-title":"Theranostics"},{"issue":"2","key":"289_CR12","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.coi.2011.12.009","volume":"24","author":"SL Topalian","year":"2012","unstructured":"Topalian SL, Drake CG, Pardoll DM. Targeting the PD-1\/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr Opin Immunol. 2012;24(2):207\u201312.","journal-title":"Curr Opin Immunol"},{"issue":"5","key":"289_CR13","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1172\/JCI73639","volume":"124","author":"A Gros","year":"2014","unstructured":"Gros A, Robbins PF, Yao X, Li YF, Turcotte S, Tran E, et al. PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors. J Clin Invest. 2014;124(5):2246\u201359.","journal-title":"J Clin Invest"},{"issue":"6","key":"289_CR14","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1084\/jem.20112741","volume":"209","author":"T Yokosuka","year":"2012","unstructured":"Yokosuka T, Takamatsu M, Kobayashi-Imanishi W, Hashimoto-Tane A, Azuma M, Saito T. Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2. J Exp Med. 2012;209(6):1201\u201317.","journal-title":"J Exp Med"},{"key":"289_CR15","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nrd4591","volume":"14","author":"KM Mahoney","year":"2015","unstructured":"Mahoney KM, Rennert PD, Freeman GJ. Combination cancer immunotherapy and new immunomodulatory targets. Nat Rev Drug Discov. 2015;14:561.","journal-title":"Nat Rev Drug Discov"},{"issue":"3","key":"289_CR16","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.febslet.2005.12.093","volume":"580","author":"L Seung-Jin","year":"2006","unstructured":"Seung-Jin L, Byeong-Churl J, Soo-Woong L, Young-Il Y, Seong-Il S, Yeong-Min P, et al. Interferon regulatory factor-1 is prerequisite to the constitutive expression and IFN-\u03b3-induced upregulation of B7-H1 (CD274). FEBS Lett. 2006;580(3):755\u201362.","journal-title":"FEBS Lett"},{"key":"289_CR17","doi-asserted-by":"crossref","unstructured":"Taube JM, Anders RA, Young GD, Xu H, Sharma R, McMiller TL, et al. Colocalization of inflammatory response with B7-H1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med. 2012;4(127):127ra37-ra37.","DOI":"10.1126\/scitranslmed.3003689"},{"key":"289_CR18","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/nrclinonc.2016.25","volume":"13","author":"DN Khalil","year":"2016","unstructured":"Khalil DN, Smith EL, Brentjens RJ, Wolchok JD. The future of cancer treatment: immunomodulation, CARs and combination immunotherapy. Nat Rev Clin Oncol. 2016;13:273\u201390.","journal-title":"Nat Rev Clin Oncol"},{"issue":"4","key":"289_CR19","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, et al. Nivolumab in previously untreated melanoma without BRAF mutation. New Engl J Med. 2015;372(4):320\u201330.","journal-title":"New Engl J Med"},{"issue":"26","key":"289_CR20","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, et al. Pembrolizumab versus ipilimumab in advanced melanoma. New Engl J Med. 2015;372(26):2521\u201332.","journal-title":"New Engl J Med"},{"issue":"3","key":"289_CR21","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S1470-2045(15)70054-9","volume":"16","author":"NA Rizvi","year":"2015","unstructured":"Rizvi NA, Mazi\u00e8res J, Planchard D, Stinchcombe TE, Dy GK, Antonia SJ, et al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol. 2015;16(3):257\u201365.","journal-title":"Lancet Oncol"},{"issue":"1","key":"289_CR22","doi-asserted-by":"crossref","first-page":"e1364828","DOI":"10.1080\/2162402X.2017.1364828","volume":"7","author":"S Simon","year":"2018","unstructured":"Simon S, Labarriere N. PD-1 expression on tumor-specific T cells: friend or foe for immunotherapy? OncoImmunology. 2018;7(1):e1364828.","journal-title":"OncoImmunology"},{"key":"289_CR23","doi-asserted-by":"crossref","unstructured":"Antonia SJ, Brahmer JR, Gettinger S, Chow LQ, Juergens R, Shepherd FA, et al. Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with platinum-based doublet chemotherapy (PT-DC) in advanced non-small cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys. 2014;90(5):\u2013S2.","DOI":"10.1016\/j.ijrobp.2014.08.024"},{"issue":"15_suppl","key":"289_CR24","doi-asserted-by":"crossref","first-page":"5010","DOI":"10.1200\/jco.2014.32.15_suppl.5010","volume":"32","author":"A Amin","year":"2014","unstructured":"Amin A, Plimack ER, Infante JR, Ernstoff MS, Rini BI, McDermott DF, et al. Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with sunitinib or pazopanib in patients (pts) with metastatic renal cell carcinoma (mRCC). J Clin Oncol. 2014;32(15_suppl):5010.","journal-title":"J Clin Oncol"},{"key":"289_CR25","doi-asserted-by":"crossref","unstructured":"Zou W, Wolchok JD, Chen L. PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: mechanisms, response biomarkers, and combinations. Sci Transl Med. 2016;8(328):328rv4-rv4.","DOI":"10.1126\/scitranslmed.aad7118"},{"key":"289_CR26","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/nri2326","volume":"8","author":"W Zou","year":"2008","unstructured":"Zou W, Chen L. Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol. 2008;8:467\u201377.","journal-title":"Nat Rev Immunol"},{"key":"289_CR27","doi-asserted-by":"crossref","unstructured":"Fujii S-I, Shimizu K, Kronenberg M, Steinman RM. Prolonged IFN-\u03b3-producing NKT response induced with \u03b1-galactosylceramide-loaded DCs. Nat Immunol. 2002;3:\u2013867.","DOI":"10.1038\/ni827"},{"key":"289_CR28","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/nrd1632","volume":"4","author":"VP Torchilin","year":"2005","unstructured":"Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov. 2005;4:145\u201360.","journal-title":"Nat Rev Drug Discov"},{"issue":"9","key":"289_CR29","doi-asserted-by":"crossref","first-page":"3384","DOI":"10.1172\/JCI80011","volume":"125","author":"L Chen","year":"2015","unstructured":"Chen L, Han X. Anti\u2013PD-1\/PD-L1 therapy of human cancer: past, present, and future. J Clin Invest. 2015;125(9):3384\u201391.","journal-title":"J Clin Invest"},{"key":"289_CR30","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1038\/nri1457","volume":"4","author":"AL Mellor","year":"2004","unstructured":"Mellor AL, Munn DH. Ido expression by dendritic cells: tolerance and tryptophan catabolism. Nat Rev Immunol. 2004;4:762\u201374.","journal-title":"Nat Rev Immunol"},{"key":"289_CR31","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/nature04754","volume":"441","author":"PR Mangan","year":"2006","unstructured":"Mangan PR, Harrington LE, O'Quinn DB, Helms WS, Bullard DC, Elson CO, et al. Transforming growth factor-\u03b2 induces development of the TH17 lineage. Nature. 2006;441:231\u20134.","journal-title":"Nature"},{"issue":"5","key":"289_CR32","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1007\/s00262-008-0591-5","volume":"58","author":"Y Liu","year":"2009","unstructured":"Liu Y, Yu Y, Yang S, Zeng B, Zhang Z, Jiao G, et al. Regulation of arginase I activity and expression by both PD-1 and CTLA-4 on the myeloid-derived suppressor cells. Cancer Immunol Immunother. 2009;58(5):687\u201397.","journal-title":"Cancer Immunol Immunother"},{"issue":"10","key":"289_CR33","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1084\/jem.20100637","volume":"207","author":"J Fourcade","year":"2010","unstructured":"Fourcade J, Sun Z, Benallaoua M, Guillaume P, Luescher IF, Sander C, et al. Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients. J Exp Med. 2010;207(10):2175\u201386.","journal-title":"J Exp Med"},{"issue":"5","key":"289_CR34","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1172\/JCI80445","volume":"125","author":"J-M Chauvin","year":"2015","unstructured":"Chauvin J-M, Pagliano O, Fourcade J, Sun Z, Wang H, Sander C, et al. TIGIT and PD-1 impair tumor antigen-specific CD8+ T cells in melanoma patients. J Clin Invest. 2015;125(5):2046\u201358.","journal-title":"J Clin Invest"},{"issue":"5","key":"289_CR35","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1158\/1078-0432.CCR-12-1630","volume":"19","author":"DT Frederick","year":"2013","unstructured":"Frederick DT, Piris A, Cogdill AP, Cooper ZA, Lezcano C, Ferrone CR, et al. BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clin Cancer Res. 2013;19(5):1225\u201331.","journal-title":"Clin Cancer Res"},{"key":"289_CR36","doi-asserted-by":"crossref","unstructured":"Chretien A-S, Le Roy A, Vey N, Prebet T, Blaise D, Fauriat C, et al. Cancer-induced alterations of NK-mediated target recognition: current and investigational pharmacological strategies aiming at restoring NK-mediated anti-tumor activity. Front Immunol. 2014;5(122).","DOI":"10.3389\/fimmu.2014.00122"},{"issue":"4","key":"289_CR37","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1158\/0008-5472.CAN-11-1620","volume":"72","author":"S-R Woo","year":"2012","unstructured":"Woo S-R, Turnis ME, Goldberg MV, Bankoti J, Selby M, Nirschl CJ, et al. Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T cell function to promote tumoral immune escape. Cancer Res. 2012;72(4):917\u201327.","journal-title":"Cancer Res"},{"key":"289_CR38","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1038\/gt.2015.29","volume":"22","author":"MR Wu","year":"2015","unstructured":"Wu MR, Zhang T, DeMars LR, Sentman CL. B7H6-specific chimeric antigen receptors lead to tumor elimination and host anti-tumor immunity. Gene Ther. 2015;22:675\u201384.","journal-title":"Gene Ther"},{"issue":"1","key":"289_CR39","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/1479-5876-5-20","volume":"5","author":"M Mansour","year":"2007","unstructured":"Mansour M, Pohajdak B, Kast WM, Fuentes-Ortega A, Korets-Smith E, Weir GM, et al. Therapy of established B16-F10 melanoma tumors by a single vaccination of CTL\/T helper peptides in VacciMax\u00ae. J Transl Med. 2007;5(1):20.","journal-title":"J Transl Med"},{"issue":"114","key":"289_CR40","first-page":"35","volume":"8","author":"Y Ming","year":"2017","unstructured":"Ming Y, Li Y, Xing H, Luo M, Li Z, Chen J, et al. Circulating tumor cells: from theory to nanotechnology-based detection. Front Pharmacol. 2017;8(114):35.","journal-title":"Front Pharmacol"},{"key":"289_CR41","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1038\/ncb3513","volume":"19","author":"AM Krebs","year":"2017","unstructured":"Krebs AM, Mitschke J, Lasierra Losada M, Schmalhofer O, Boerries M, Busch H, et al. The EMT-activator Zeb1 is a key factor for cell plasticity and promotes metastasis in pancreatic cancer. Nat Cell Biol. 2017;19:518\u201329.","journal-title":"Nat Cell Biol"},{"key":"289_CR42","doi-asserted-by":"crossref","first-page":"5241","DOI":"10.1038\/ncomms6241","volume":"5","author":"L Chen","year":"2014","unstructured":"Chen L, Gibbons DL, Goswami S, Cortez MA, Ahn Y-H, Byers LA, et al. Metastasis is regulated via microRNA-200\/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression. Nat Commun. 2014;5:5241.","journal-title":"Nat Commun"},{"issue":"8","key":"289_CR43","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1200\/JCO.2012.45.8703","volume":"31","author":"JR Brahmer","year":"2013","unstructured":"Brahmer JR. Harnessing the immune system for the treatment of non-small-cell lung cancer. J Clin Oncol. 2013;31(8):1021\u20138.","journal-title":"J Clin Oncol"},{"issue":"17","key":"289_CR44","doi-asserted-by":"crossref","first-page":"7875","DOI":"10.1073\/pnas.1003345107","volume":"107","author":"J Matsuzaki","year":"2010","unstructured":"Matsuzaki J, Gnjatic S, Mhawech-Fauceglia P, Beck A, Miller A, Tsuji T, et al. Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer. Proc Natl Acad Sci. 2010;107(17):7875\u201380.","journal-title":"Proc Natl Acad Sci"},{"key":"289_CR45","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/nature14292","volume":"520","author":"C Twyman-Saint Victor","year":"2015","unstructured":"Twyman-Saint Victor C, Rech AJ, Maity A, Rengan R, Pauken KE, Stelekati E, et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature. 2015;520:373\u20137.","journal-title":"Nature"},{"key":"289_CR46","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1038\/nrd3794","volume":"11","author":"P Miossec","year":"2012","unstructured":"Miossec P, Kolls JK. Targeting IL-17 and TH17 cells in chronic inflammation. Nat Rev Drug Discov. 2012;11:763.","journal-title":"Nat Rev Drug Discov"}],"updated-by":[{"DOI":"10.1208\/s12248-025-01027-8","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T00:00:00Z","timestamp":1738540800000}}],"container-title":["The AAPS Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-018-0289-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1208\/s12248-018-0289-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-018-0289-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T20:36:11Z","timestamp":1738614971000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1208\/s12248-018-0289-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,11]]},"references-count":46,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2019,3]]}},"alternative-id":["289"],"URL":"https:\/\/doi.org\/10.1208\/s12248-018-0289-3","relation":{},"ISSN":["1550-7416"],"issn-type":[{"value":"1550-7416","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,11]]},"assertion":[{"value":"31 August 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1208\/s12248-025-01027-8","URL":"https:\/\/doi.org\/10.1208\/s12248-025-01027-8","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare that they have no conflict of interest","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}],"article-number":"18"}}